Report Overview

The Canada Asthma Drug market size stood at around USD XX billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period.

In Canada, it is the third most common chronic disease. the most affected people in Canada are children and asthma continues to be a major cause of hospitalization for children in Canada. At present, more than 3.8 million Canadians are living with asthma it is roughly 9.5% of the total population of Canada. 317 Canadians are diagnosed with asthma every day. Canadians have a two in five chance or a 40% risk of being diagnosed with asthma before age 40. the risk of developing asthma is greatest during childhood, with 20% of children being diagnosed as asthmatic by 12 years of age. A further 20% of individuals will be diagnosed between the ages of 12 and 40 years. The high level of air pollution and a significant number of smokers in Canada is boosting the demand for inhalers in the country.



Market Drivers

The increasing prevalence of asthma is a major driver fuelling the growth of this market in Canada. The other drivers can be considered as the increasing need for better clinical and therapeutics for asthma in the light of the covid-19 pandemic. In Canada, approximately 250 people die each year from asthma. Asthma deaths can be prevented with proper asthma education. An increasing number of product launches are expected to drive the growth of the asthma drug market. An increase in the awareness programs and initiatives to support the major pharmaceutical players to implement advanced R&D and drug development will boost this market in Canada.